Scarica l'app Stockscreener
1.38
8.66%
0.11
Pre-mercato:
1.50
0.12
+8.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Maxcyte Inc Borsa (MXCT) Ultime notizie
Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 - Investing.com
Maxcyte CFO Swirsky buys $64.5k in shares - Investing.com
Erck Stanley C, Maxcyte director, buys $137k in MXCT stock - Investing.com
MaxCyte Executives and Directors Acquire Shares - TradingView
Should value investors consider MaxCyte Inc.Game-Changing Investment Alerts - thegnnews.com
MaxCyte Inc. Breaks Losing Streak — Is the Trend ReversingFree Premium Stock Market Reports - beatles.ru
Chartists Watching For Breakout in MaxCyte Inc.Weekly Return Pick Forecast Reports Show Trend - beatles.ru
MaxCyte Chief Commercial Officer Departs Amid Severance Agreement - TipRanks
BTIG Downgrades MaxCyte to Neutral Citing Ongoing Challenges for Cell and Gene Therapy Customers - AInvest
MaxCyte Shares Plummet After Analyst Downgrades and Missed Earnings Estimates - AInvest
MaxCyte Shares Fall After BTIG Downgrade - MarketScreener
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
BTIG Downgrades MaxCyte to Neutral From Buy - MarketScreener
MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns - Investing.com Nigeria
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
MaxCyte signs platform license agreement with Adicet Bio - MSN
MaxCyte Inc Q2 2025 Earnings: Revenue Falls Short at $8.5 Million, Net Loss Widens to $12.4 Million - AInvest
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript - Insider Monkey
Maxcyte, Inc. shares rise 1.40% after-hours despite William Blair downgrading to Market Perform. - AInvest
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates - MSN
MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation - MSN
Maxcyte's 31% Intraday Plunge: Earnings Woes and Sector Turbulence Spark Investor Panic - AInvest
MaxCyte Disappoints With Lower Revenue And Guidance For 2025 - Finimize
William Blair Downgrades MaxCyte to Market Perform From Outperform - MarketScreener
MaxCyte downgraded to Market Perform from Outperform at William Blair - TipRanks
Maxcyte, Inc. shares fall 11.76% premarket after Q2 revenue misses analyst estimates. - AInvest
MaxCyte stock downgraded by William Blair to Market Perform on weak guidance - Investing.com Australia
MaxCyte's Q2 2025 Earnings Call: Unpacking Key Contradictions in Growth and Manufacturing Strategy - AInvest
MaxCyte Updates 2025 Revenue Guidance to $29.5M-$32.5M Amid Customer Program Consolidation - AInvest
Earnings call transcript: MaxCyte misses Q2 revenue forecast amidst stock dip - Investing.com
MaxCyte (MXCT) Q2 Revenue Drops 18% - AOL.com
Maxcyte 2025 Q2 Earnings Worse Performance as Net Loss Widens 31.8% - AInvest
MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges - Investing.com Nigeria
MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges By Investing.com - Investing.com South Africa
Cell-engineering firm MaxCyte Q2 revenue misses analyst estimates - MarketScreener
MaxCyte Reports Q2 2025 Financial Results - TipRanks
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance - Morningstar
MaxCyte Partners with Adicet Bio for Gamma Delta T Cell Therapy Platform License Agreement - AInvest
MaxCyte Inks Strategic Platform License with Adicet Bio, Entitled to Licensing Fees and Revenue - AInvest
Maxcyte signs platform license agreement with Adicet Bio - MarketScreener
MaxCyte Signs Platform License Agreement with Adicet Bio - The Manila Times
MaxCyte, Adicet Bio Sign Strategic Platform License Agreement - AInvest
MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Adicet's Cancer Treatment Innovation - Stock Titan
Heatmap Data Shows High Activity in MaxCyte Inc. SectorInvestment Strategy Designed for Capital Protection - beatles.ru
What are analysts’ price targets for MaxCyte Inc. in the next 12 monthsBreakout profit opportunities - Jammu Links News
How does MaxCyte Inc. generate profit in a changing economyLightning-fast growth - Jammu Links News
What are the latest earnings results for MaxCyte Inc.Achieve breakthrough financial results - Jammu Links News
What institutional investors are buying MaxCyte Inc. stockFind the best stocks for sustainable growth - Jammu Links News
What analysts say about MaxCyte Inc. stockInvest confidently with professional market insights - Jammu Links News
What is MaxCyte Inc. company’s growth strategyBuild a strong portfolio for long-term success - Jammu Links News
What are the technical indicators suggesting about MaxCyte Inc.Build wealth steadily with smart stock selection - Jammu Links News
Should I hold or sell MaxCyte Inc. stock in 2025Maximize gains with data-driven trading alerts - Jammu Links News
Exit strategy if you’re trapped in MaxCyte Inc.Chart Risk Profile for Capital Preservation - Newser
MaxCyte announces strategic platform licensing agreement with Anocca AB to advance TCR-T cell therapy pipeline - MarketScreener
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline - The Manila Times
0.31%
1.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):